BUZZ-Anavex rises after schizophrenia drug meets main goal in study

Reuters

Oct 02, 2025

** Shares of Anavex Life Sciences AVXL.O rise 5.4% to $9.5 premarket

** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study

** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL

** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.

** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking

** As of last close, stock had fallen ~16% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572171375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572171375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572171375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572171375","market":"nz","top_or_hot":-1,"title":"BUZZ-Anavex rises after schizophrenia drug meets main goal in study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Anavex rises after schizophrenia drug meets main goal in study</title></head><body><p>** Shares of <a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences <span>AVXL.O</span> rise 5.4% to $9.5 premarket </p><p>** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study</p><p>** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL </p><p>** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.</p><p>** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking</p><p>** As of last close, stock had fallen ~16% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Mariam.ESunny@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Anavex rises after schizophrenia drug meets main goal in study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Anavex rises after schizophrenia drug meets main goal in study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 20:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Anavex rises after schizophrenia drug meets main goal in study</title></head><body><p>** Shares of <a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences <span>AVXL.O</span> rise 5.4% to $9.5 premarket </p><p>** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study</p><p>** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL </p><p>** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.</p><p>** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking</p><p>** As of last close, stock had fallen ~16% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Mariam.ESunny@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nL3N3VJ0QS:1","article_id":"2572171375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572171375","pubTimestamp":1759409981,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Anavex rises after schizophrenia drug meets main goal in study** Shares of Anavex Life Sciences AVXL.O rise 5.4% to $9.5 premarket ** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL ** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking** As of last close, stock had fallen ~16% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVXL":"Anavex Life Sciences Corp."},"translate_title":"精神分裂症药物达到研究主要目标后，BUZZ-Anavex上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":0.9},"content_text":"BUZZ-Anavex rises after schizophrenia drug meets main goal in study** Shares of Anavex Life Sciences AVXL.O rise 5.4% to $9.5 premarket ** Company says its experimental schizophrenia drug was shown to be safe and well-tolerated, meeting the main goal in a mid-stage study** The drug, ANAVEX3-71, aims to treat adults with schizophrenia who are on stable antipsychotic medication -AVXL ** Company says ANAVEX3-71 is designed to treat symptoms associated with the mental health disorder without the side effects of standard of care antipsychotics.** Schizophrenia is a mental disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions, causing hallucinations, delusions and impaired thinking** As of last close, stock had fallen ~16% YTD (Reporting by Sahil Pandey in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}